ATE95698T1 - Verhinderung von entzugserscheinungen. - Google Patents

Verhinderung von entzugserscheinungen.

Info

Publication number
ATE95698T1
ATE95698T1 AT90403284T AT90403284T ATE95698T1 AT E95698 T1 ATE95698 T1 AT E95698T1 AT 90403284 T AT90403284 T AT 90403284T AT 90403284 T AT90403284 T AT 90403284T AT E95698 T1 ATE95698 T1 AT E95698T1
Authority
AT
Austria
Prior art keywords
radical
aryl
alkyl
hydrogen atom
image
Prior art date
Application number
AT90403284T
Other languages
English (en)
Inventor
Jordi Frigola-Constansa
Juan Pares-Corominas
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Application granted granted Critical
Publication of ATE95698T1 publication Critical patent/ATE95698T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Flanged Joints, Insulating Joints, And Other Joints (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Lubricants (AREA)
  • Ceramic Products (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Surgical Instruments (AREA)
  • Paper (AREA)
  • Saccharide Compounds (AREA)
AT90403284T 1989-11-22 1990-11-21 Verhinderung von entzugserscheinungen. ATE95698T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8915316A FR2654621B1 (fr) 1989-11-22 1989-11-22 Inhibition du syndrome d'abstinence.
EP90403284A EP0429360B1 (de) 1989-11-22 1990-11-21 Verhinderung von Entzugserscheinungen

Publications (1)

Publication Number Publication Date
ATE95698T1 true ATE95698T1 (de) 1993-10-15

Family

ID=9387643

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90403284T ATE95698T1 (de) 1989-11-22 1990-11-21 Verhinderung von entzugserscheinungen.

Country Status (16)

Country Link
US (1) US5162323A (de)
EP (1) EP0429360B1 (de)
JP (1) JPH0699309B2 (de)
KR (1) KR950007230B1 (de)
AT (1) ATE95698T1 (de)
AU (1) AU628237B2 (de)
CA (1) CA2030401C (de)
DE (1) DE69003924T2 (de)
DK (1) DK0429360T3 (de)
ES (1) ES2034909A6 (de)
FR (1) FR2654621B1 (de)
HU (1) HU207797B (de)
NO (1) NO905028L (de)
PT (1) PT95949B (de)
RU (1) RU2042674C1 (de)
ZA (1) ZA909256B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712392A (en) * 1990-12-28 1998-01-27 Neurogen Corporation Certain 4-piperidine- and piperazinoalkyl-2-phenyl imidazole derivatives; dopamine receptor subtype specific ligands
US5681956A (en) * 1990-12-28 1997-10-28 Neurogen Corporation 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands
FR2671972B1 (fr) * 1991-01-25 1995-03-03 Esteve Labor Dr Utilisation de derives 1-h-azole-(omega-(4-(2-pyrimidinyl)-1-piperazinyl)-alkyl) pour la preparation de medicaments destines au traitement des troubles des fonctions cognitives.
FR2701260B1 (fr) * 1993-02-05 1995-05-05 Esteve Labor Dr Dérivés de 2-[4-(4-azolylbutyl)-1-pipérazinyl]-5-hydroxypyrimidine, leur préparation et leur application en tant que médicaments.
FR2705098B1 (fr) * 1993-05-10 1995-08-04 Esteve Labor Dr Procédé de préparation de 2-{4-[4-(chloro-1-pyrazolyl)butyl]1-pipérazinyl}pyrimidine (Lesopitron) .
ES2099031B1 (es) * 1995-05-31 1997-12-01 Esteve Labor Dr Nuevos polimorfos de diclorhidrato de lesopitron y sus formas hidratadas, procedimientos de preparacion y composiciones que los contienen.
US6166205A (en) * 1998-09-02 2000-12-26 Neurogen Corporation 2-Aryl-4-(1-[4-heteroaryl]piperazin-1-yl)methylimidazoles: dopamine . D.sub4 receptor subtype ligands
FR2797399B1 (fr) * 1999-08-13 2002-10-18 Aventis Pharma Sa Utilisation de la cyamemazine dans le traitement du sevrage aux benzodiazepines
ES2167276B1 (es) * 2000-10-20 2003-04-01 Esteve Labor Dr Nuevos derivados de cianoaril (o cianoheteroaril)-carbonil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos.
EP1749525A1 (de) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Zusammensetzung enthaltend substituierte Pyrazoline und gegen Sucht wirksame Mittel
WO2007009691A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Combination of substituted pyrazolines and anti -addictive agent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777173A (en) * 1987-03-25 1988-10-11 Bristol-Myers Company Method for treatment of alcohol abuse
FR2642759B1 (fr) * 1989-02-09 1991-05-17 Laboratorios Esteve Sa Derives de pyrimidyl-piperazinyl-alkyl azoles avec activite anxiolytique et/ou tranquillisante

Also Published As

Publication number Publication date
US5162323A (en) 1992-11-10
DK0429360T3 (da) 1993-12-13
CA2030401A1 (fr) 1991-05-23
NO905028L (no) 1991-05-23
EP0429360A2 (de) 1991-05-29
NO905028D0 (no) 1990-11-20
AU6676790A (en) 1991-05-30
KR950007230B1 (ko) 1995-07-07
PT95949B (pt) 1998-01-30
AU628237B2 (en) 1992-09-10
EP0429360A3 (en) 1991-09-25
ZA909256B (en) 1991-10-30
DE69003924D1 (de) 1993-11-18
RU2042674C1 (ru) 1995-08-27
FR2654621A1 (fr) 1991-05-24
HU207797B (en) 1993-06-28
HUT56093A (en) 1991-07-29
DE69003924T2 (de) 1994-02-24
JPH0699309B2 (ja) 1994-12-07
JPH03176422A (ja) 1991-07-31
HU907230D0 (en) 1991-05-28
EP0429360B1 (de) 1993-10-13
CA2030401C (fr) 2000-03-07
FR2654621B1 (fr) 1994-09-23
KR910009268A (ko) 1991-06-28
ES2034909A6 (es) 1993-04-01
PT95949A (pt) 1991-09-13

Similar Documents

Publication Publication Date Title
EA200000592A1 (ru) Азаполициклические соединения, конденсированные с арилом
NZ231983A (en) Substituted 1,3-diazoles and 1,2,4-triazoles; fungicidal compositions, methods for preparation and combating fungal disease
ATE95698T1 (de) Verhinderung von entzugserscheinungen.
ATE73790T1 (de) Amino 5,6,7,8tetrahydronaphtho(2,3b>furanderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
EA200100516A1 (ru) Производные 3,3-биарилпиперидина и 2,2-биарилморфолина
DE2961352D1 (en) 4-phenyl-thiazolyl-2-oxamate derivatives, their preparation and their use in the treatment of asthma
DE69418744D1 (de) Verwendung von Pregnanderivaten zur Behandlung von Tumoren
ATE37533T1 (de) Derivate der 4-phenyl-4-oxo-buten-2-saeure, verfahren zu ihrer herstellung, medikamente und mischungen mit diesen derivaten.
JPS56152465A (en) Aminoalkoxypyrazole, its manufacture and medicine containing it
ATE19244T1 (de) 2-piperazinyl-4-phenyl-quinazolin-derivate mit antidepressiven eigenschaften, verfahren zu deren herstellung und diese enthaltende arzneimitteln.
DE3669514D1 (de) Neue anthracycline und diese enthaltende arzneimittel.
ZA903944B (en) Pyrrolidone derivatives the process for their preparation and the pharmaceutical compositions containing them
DE3862660D1 (de) 2,3-dihydro-2-oxo-3-benzofuranyl-essigsaeurederivate und diese enthaltende arzneimittel.
ATE96803T1 (de) Indolo(3,2,1-de>(1,4>-oxazino(2,3,4ij>(1,5>naphthyridinderivate, verfahren zu ihrer herstellung und zwischenprodukte, ihre verwendung als arzneimittel und diese enthaltende zubereitungen.
ATE53839T1 (de) 2,3-dihydro-3-phenyl-benzofuran-2-onacetamidderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
HUT55013A (en) Process for producing substituted 20,21-dinoreburnamenine
ES8307798A1 (es) Un procedimiento para la preparacion de derivados de piperazilmetil-4-dibenzofuranona, o, dibenzofuranol.
NZ234924A (en) 1,3-oxazine derivatives and antitussive compositions
DK0423870T3 (da) Dibenzodioxazecin- dibenzodioxaazacycloundecinderivater

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee